153 related articles for article (PubMed ID: 32681754)
1. Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma.
Raswoli M; Nobre L; Hawkins C; Bartels UK; Tabori U; Bouffet E
Pediatr Blood Cancer; 2021 Jan; 68(1):e28561. PubMed ID: 32681754
[No Abstract] [Full Text] [Related]
2. Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.
Levin VA; Lamborn K; Wara W; Davis R; Edwards M; Rabbitt J; Malec M; Prados MD
Neuro Oncol; 2000 Jan; 2(1):22-8. PubMed ID: 11302250
[TBL] [Abstract][Full Text] [Related]
3. Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas.
Lancaster DL; Hoddes JA; Michalski A
J Neurooncol; 2003 Jul; 63(3):289-94. PubMed ID: 12892235
[TBL] [Abstract][Full Text] [Related]
4. Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Baumert BG; Stupp R; ;
Ann Oncol; 2008 Sep; 19 Suppl 7():vii217-22. PubMed ID: 18790954
[No Abstract] [Full Text] [Related]
5. Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
Kyritsis AP; Yung WK; Jaeckle KA; Bruner J; Gleason MJ; Ictech SE; Flowers A; Levin VA
Neurosurgery; 1996 Nov; 39(5):921-6. PubMed ID: 8905746
[TBL] [Abstract][Full Text] [Related]
6. One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
Keogh RJ; Aslam R; Hennessy MA; Coyne Z; Hennessy BT; Breathnach OS; Grogan L; Morris PG
BMC Cancer; 2021 Feb; 21(1):140. PubMed ID: 33557783
[TBL] [Abstract][Full Text] [Related]
7. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
8. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.
Ater JL; Zhou T; Holmes E; Mazewski CM; Booth TN; Freyer DR; Lazarus KH; Packer RJ; Prados M; Sposto R; Vezina G; Wisoff JH; Pollack IF
J Clin Oncol; 2012 Jul; 30(21):2641-7. PubMed ID: 22665535
[TBL] [Abstract][Full Text] [Related]
9. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
10. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.
Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T
Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796
[TBL] [Abstract][Full Text] [Related]
11. Aggressive oligodendroglioma: a chemosensitive tumor.
Cairncross JG
Recent Results Cancer Res; 1994; 135():127-33. PubMed ID: 8047688
[No Abstract] [Full Text] [Related]
12. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Levin VA
Oncology (Williston Park); 2015 Apr; 29(4):264, 266-8. PubMed ID: 25952490
[No Abstract] [Full Text] [Related]
13. [Dabrafénib and tramétinib in BRAF V600E mutated pediatric gliomas].
Giorgis O; Doz F
Bull Cancer; 2024 May; 111(5):429-430. PubMed ID: 38471994
[No Abstract] [Full Text] [Related]
14. Chemosensitivity testing in the treatment of malignant gliomas.
Darling JL
Prog Exp Tumor Res; 1985; 29():123-30. PubMed ID: 4070628
[No Abstract] [Full Text] [Related]
15. Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas.
Jakacki RI; Jamison C; Mathews VP; Heilman DK; Dropcho E; Cornetta K; Macdonald DR; Williams DA
Med Pediatr Oncol; 1998 Dec; 31(6):483-90. PubMed ID: 9835900
[TBL] [Abstract][Full Text] [Related]
16. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen.
Prados MD; Edwards MS; Rabbitt J; Lamborn K; Davis RL; Levin VA
J Neurooncol; 1997 May; 32(3):235-41. PubMed ID: 9049885
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
DeAngelis LM
J Clin Oncol; 2009 Dec; 27(35):5861-2. PubMed ID: 19901101
[No Abstract] [Full Text] [Related]
18. [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma].
Bouffet E; Mornex F; Jouvet A; Thiesse P; Mertens P; Helfre S; Sindou M; Bret P
Bull Cancer; 1997 Oct; 84(10):951-6. PubMed ID: 9435796
[TBL] [Abstract][Full Text] [Related]
19. Predictive biomarkers in adult gliomas: the present and the future.
Thomas L; Di Stefano AL; Ducray F
Curr Opin Oncol; 2013 Nov; 25(6):689-94. PubMed ID: 24076583
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
Yang SH; Hong YK; Yoon SC; Kim BS; Lee YS; Lee TK; Lee KS; Jeun SS; Kim MC; Park CK
Oncol Rep; 2007 Jun; 17(6):1359-64. PubMed ID: 17487391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
